These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 7757072)

  • 1. Slow N-acetylation genotype is a susceptibility factor in occupational and smoking related bladder cancer.
    Risch A; Wallace DM; Bathers S; Sim E
    Hum Mol Genet; 1995 Feb; 4(2):231-6. PubMed ID: 7757072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of N-acetylation polymorphisms in smoking-associated bladder cancer: evidence of a gene-gene-exposure three-way interaction.
    Taylor JA; Umbach DM; Stephens E; Castranio T; Paulson D; Robertson C; Mohler JL; Bell DA
    Cancer Res; 1998 Aug; 58(16):3603-10. PubMed ID: 9721868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of N-acetyl transferase 1 and 2 polymorphisms on bladder cancer risk in Caucasians.
    Gu J; Liang D; Wang Y; Lu C; Wu X
    Mutat Res; 2005 Mar; 581(1-2):97-104. PubMed ID: 15725609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic polymorphisms of N-acetyltransferase 1 and 2 and risk of cigarette smoking-related bladder cancer.
    Hsieh FI; Pu YS; Chern HD; Hsu LI; Chiou HY; Chen CJ
    Br J Cancer; 1999 Oct; 81(3):537-41. PubMed ID: 10507782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current smoking, occupation, N-acetyltransferase-2 and bladder cancer: a pooled analysis of genotype-based studies.
    Vineis P; Marinelli D; Autrup H; Brockmoller J; Cascorbi I; Daly AK; Golka K; Okkels H; Risch A; Rothman N; Sim E; Taioli E
    Cancer Epidemiol Biomarkers Prev; 2001 Dec; 10(12):1249-52. PubMed ID: 11751441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Arylamine N-acetyltransferase 1 (NAT1) and 2 (NAT2) polymorphisms in susceptibility to bladder cancer: the influence of smoking.
    Okkels H; Sigsgaard T; Wolf H; Autrup H
    Cancer Epidemiol Biomarkers Prev; 1997 Apr; 6(4):225-31. PubMed ID: 9107426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses.
    García-Closas M; Malats N; Silverman D; Dosemeci M; Kogevinas M; Hein DW; Tardón A; Serra C; Carrato A; García-Closas R; Lloreta J; Castaño-Vinyals G; Yeager M; Welch R; Chanock S; Chatterjee N; Wacholder S; Samanic C; Torà M; Fernández F; Real FX; Rothman N
    Lancet; 2005 Aug 20-26; 366(9486):649-59. PubMed ID: 16112301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cigarette smoking, N-acetyltransferase 2 acetylation status, and bladder cancer risk: a case-series meta-analysis of a gene-environment interaction.
    Marcus PM; Hayes RB; Vineis P; Garcia-Closas M; Caporaso NE; Autrup H; Branch RA; Brockmöller J; Ishizaki T; Karakaya AE; Ladero JM; Mommsen S; Okkels H; Romkes M; Roots I; Rothman N
    Cancer Epidemiol Biomarkers Prev; 2000 May; 9(5):461-7. PubMed ID: 10815690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N-acetyltransferase 2 phenotype, occupation, and bladder cancer risk: results from the EPIC cohort.
    Pesch B; Gawrych K; Rabstein S; Weiss T; Casjens S; Rihs HP; Ding H; Angerer J; Illig T; Klopp N; Bueno-de-Mesquita B; Ros MM; Kaaks R; Chang-Claude J; Roswall N; Tjønneland A; Overvad K; Clavel-Chapelon F; Boutron-Ruault MC; Dossus L; Boeing H; Weikert S; Trichopoulos D; Palli D; Sieri S; Tumino R; Panico S; Quirós JR; González C; Sánchez MJ; Dorronsoro M; Navarro C; Barricarte A; Ljungberg B; Johansson M; Ulmert D; Ehrnström R; Khaw KT; Wareham N; Key TJ; Ferrari P; Romieu I; Riboli E; Brüning T; Vineis P
    Cancer Epidemiol Biomarkers Prev; 2013 Nov; 22(11):2055-65. PubMed ID: 24092628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Refinement of the prediction of N-acetyltransferase 2 (NAT2) phenotypes with respect to enzyme activity and urinary bladder cancer risk.
    Selinski S; Blaszkewicz M; Ickstadt K; Hengstler JG; Golka K
    Arch Toxicol; 2013 Dec; 87(12):2129-39. PubMed ID: 24221535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence for an intensity-dependent interaction of NAT2 acetylation genotype and cigarette smoking in the Spanish Bladder Cancer Study.
    Lubin JH; Kogevinas M; Silverman D; Malats N; Garcia-Closas M; Tardón A; Hein DW; Garcia-Closas R; Serra C; Dosemeci M; Carrato A; Rothman N
    Int J Epidemiol; 2007 Feb; 36(1):236-41. PubMed ID: 17510079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genotyping of the polymorphic N-acetyltransferase (NAT2) and loss of heterozygosity in bladder cancer patients.
    Schnakenberg E; Ehlers C; Feyerabend W; Werdin R; Hübotter R; Dreikorn K; Schloot W
    Clin Genet; 1998 May; 53(5):396-402. PubMed ID: 9660060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GSTM1 null and NAT2 slow acetylation genotypes, smoking intensity and bladder cancer risk: results from the New England bladder cancer study and NAT2 meta-analysis.
    Moore LE; Baris DR; Figueroa JD; Garcia-Closas M; Karagas MR; Schwenn MR; Johnson AT; Lubin JH; Hein DW; Dagnall CL; Colt JS; Kida M; Jones MA; Schned AR; Cherala SS; Chanock SJ; Cantor KP; Silverman DT; Rothman N
    Carcinogenesis; 2011 Feb; 32(2):182-9. PubMed ID: 21037224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NAT2 slow acetylation and bladder cancer in workers exposed to benzidine.
    Carreón T; Ruder AM; Schulte PA; Hayes RB; Rothman N; Waters M; Grant DJ; Boissy R; Bell DA; Kadlubar FF; Hemstreet GP; Yin S; LeMasters GK
    Int J Cancer; 2006 Jan; 118(1):161-8. PubMed ID: 16003747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NAT2 gene polymorphism as a possible marker for susceptibility to bladder cancer in Japanese.
    Inatomi H; Katoh T; Kawamoto T; Matsumoto T
    Int J Urol; 1999 Sep; 6(9):446-54. PubMed ID: 10510890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymorphism of N-acetyltransferase 2 (NAT2) gene polymorphism in shanghai population: occupational and non-occupational bladder cancer patient groups.
    Ma QW; Lin GF; Chen JG; Xiang CQ; Guo WC; Golka K; Shen JH
    Biomed Environ Sci; 2004 Sep; 17(3):291-8. PubMed ID: 15602826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of genotypes of carcinogen-metabolizing enzymes and smoking status with bladder cancer in a Japanese population.
    Cui X; Lu X; Hiura M; Omori H; Miyazaki W; Katoh T
    Environ Health Prev Med; 2013 Mar; 18(2):136-42. PubMed ID: 22961351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N-acetyltransferase-2 and medical history in bladder cancer cases with a suspected occupational disease (BK 1301) in Germany.
    Weistenhofer W; Blaszkewicz M; Bolt HM; Golka K
    J Toxicol Environ Health A; 2008; 71(13-14):906-10. PubMed ID: 18569594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tobacco use and occupational exposure to carcinogens, but not N-acetyltransferase 2 genotypes are major risk factors for bladder cancer in the Japanese.
    Kontani K; Kawakami M; Nakajima T; Katsuyama T
    Urol Res; 2001 Jun; 29(3):199-204. PubMed ID: 11482447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of N-acetyltransferase (NAT) in cultured human uroepithelial cells.
    Kloth MT; Gee RL; Messing EM; Swaminathan S
    Carcinogenesis; 1994 Dec; 15(12):2781-7. PubMed ID: 8001235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.